Release issued 26th October 2007

The facility comprises a £1.5m overdraft facility with interest at 1.75% per annum over base rate and a £4.5m five year revolving credit facility with interest at 1.75% per annum over LIBOR.  The facilities are secured by a debenture over group assets.

All of the group companies will be changing banking facilities to Fortis or their banking partner.  This will consolidate the group's banking arrangements and provide the flexibility required as the group continues to grow rapidly.

Richard Trevillion, Chief Executive, Meldex International, said:

"This additional finance facility provides the Company with the flexibility, without further dilution to shareholders, to meet its objectives for both organic growth and to maximise its acquisitive growth.  We are pleased to be working with Fortis who we believe to be the right finance partner for the Company at this stage of its development.”

For further information:

About Meldex International Plc

Meldex International plc is an innovative specialty pharmaceutical and OTC product. Listed on London's AIM in May 2003, the Company has over 80 patents granted or in application within 24 patent families and has product development agreements and strategic alliances with several global healthcare companies. Meldex has acquired sales and marketing resources within Europe and the US as a launch mechanism for its own pharmaceutical products. Meldex acquired the Melbrosin business in June 2007 for a consideration of up to €35m. Melbrosin's focus is on consumer over the counter health care products based on substances of natural and plant origin which are developed into consumer orientated brands then scaled, produced and distributed by Melbrosin. The Melbrosin complements the prescription pharmaceutical sales and marketing business created and expanded in 2006.

The business continues to develop innovative delivery mechanisms enhancing both its own product range and those of selected partners using its proprietary XGEL™ polymer technology. For further information please go to www.meldexinternational.com

(16th October 2007) Launch of Dexo Germany & XGEL™ manufacturing contract

(4th October 2007) SlimThru™ existing distribution expanded and to be sold in Tesco stores

(13th September 2007) BioProgress plc completes name change to Meldex International Plc